Open-label study to determine how prior therapy with alendronate [alendronic acid] or risedronate [risedronic acid] in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide.
Phase of Trial: Phase IV
Latest Information Update: 19 Oct 2015
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms OPTAMISE
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 12 Jul 2011 Additional trial location (Germany) added as reported by European Clinical Trials Database.
- 12 Jul 2011 New source added and integrated (European Clinical Trials Database, EudraCT2004-002317-37).